Skip to content Skip to footer
Subscribe Now

NEWS

Garda to Acquire Assertio for ~$125.1M Upfront
Shots: Garda Therapeutics has entered into a definitive agreement to acquire Assertio, delisting it from Nasdaq As per the deal, Garda will acquire Assertio for $18/share in cash (~$125.1M) plus a non-tradeable CVR related to potential future milestones for Sprix, with the deal expected to close in Q2’26 & remaining shares acquired later via a…
April 9, 2026
Anumana Secures the US FDA 510(k) Clearance for its ECG-AI Algorithm to Detect Risk of Cardiac Amyloidosis Early
Shots: The US FDA has granted clearance to ECG-AI algorithm, a software-as-a-medical-device designed for cardiac amyloidosis (CA), cleared for use with standard 12-lead ECGs ECG-AI algorithm analyzes ECG waveforms to detect CA-related patterns not visible to clinicians, integrating into existing workflows using routine ECGs without additional testing to help identify at-risk pts & guide next…
April 9, 2026
Halozyme Licenses Hypercon Technology to Vertex for Convenient Drug Delivery
Shots: Halozyme Therapeutics, via its subsidiary Halozyme Hypercon, has entered a global exclusive collaboration & license agreement with Vertex to utilize its Hypercon technology across up to three drug targets  As per the deal, Halozyme will receive $15M upfront, with additional milestone payments & royalties tied to products developed using the technology Hypercon is a…
April 8, 2026
GSK
GSK’s Exdensur (Depemokimab) Receives the NMPA Approval for CRSwNP
Shots: The NMPA has approved Exdensur as an add-on therapy for adults with CRSwNP for whom therapy with systemic corticosteroids & /or surgery do not provide adequate disease control, based on P-III (ANCHOR 1 & 2) trials The ANCHOR-1 & ANCHOR-2 trial assessed Exdensur(Q6M)+ intranasal corticosteroids (SoC) vs PBO + SoC in 271 & 257 pts,…
April 8, 2026
Biocon Launches Bosaya and Aukelso (Biosimilar, Prolia & Xgeva) in the US
Shots: Biocon has reported the commercial launch of Bosaya & Aukelso, an interchangeable biosimilar version of Prolia & Xgeva (Denosumab) in the US, following FDA approval in Sep 2025  Bosaya will be available in the 60mg/mL PFS format, while Aukelso will be available as 120mg/1.7 mL (70mg/mL) single-dose vial, both for subcutaneous use Denosumab is a…
April 8, 2026
Gilead to Acquire Tubulis for ~$5B
Shots: Gilead has entered into a definitive agreement to acquire Tubulis, making it an ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation As per the deal, Gilead will acquire Tubulis for $3.15B upfront & ~$1.85B in contingent milestone payments; closing is expected in Q2’26 Acquisition will expand…
April 8, 2026
Biogen Collaborates with Alloy Therapeutics to Advance Antisense Therapeutics
Shots: Alloy Therapeutics has entered into a collaboration & license agreement with Biogen to advance antisense therapeutics against multiple undisclosed targets using Alloy’s AntiClastic ASO Platform As per the deal, Alloy will receive an upfront payment, along with additional milestone payments & tiered royalties on any products resulting from the collaboration The AntiClastic ASO platform…
April 7, 2026
Load more